Qian CN, Zhang W, Xu RH. Defeating cancer: the 150 most important questions in cancer research and clinical oncology. Chin J Cancer. 2016;35:104.
Article
PubMed
PubMed Central
Google Scholar
Wee JT, Poh SS. The most important questions in cancer research and clinical oncology. Question 1. Could the vertical transmission of human papilloma virus (HPV) infection account for the cause, characteristics, and epidemiology of HPV-positive oropharyngeal carcinoma, non-smoking East Asian female lung adenocarcinoma, and/or East Asian triple-negative breast carcinoma? Chin J Cancer. 2017;36:13.
Article
PubMed
PubMed Central
Google Scholar
Venniyoor A. The most important questions in cancer research and clinical oncology: question 2–5. Obesity-related cancers: more questions than answers. Chin J Cancer. 2017;36:18.
Article
PubMed
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 6–14. Chin J Cancer. 2017;36:33.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 15–24. Chin J Cancer. 2017;36:39.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 25–30. Chin J Cancer. 2017;36:42.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 31–39. Chin J Cancer. 2017;36:48.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 40–49. Chin J Cancer. 2017;36:55.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 50–56. Chin J Cancer. 2017;36:69.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 57–66. Chin J Cancer. 2017;36:79.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 67–75. Chin J Cancer. 2017;36:86.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 76–85. Chin J Cancer. 2017;36:91.
Article
Google Scholar
Rosenbaum E, Gautier H, Fobair P, Neri E, Festa B, Hawn M, Andrews A, Hirschberger N, Selim S, Spiegal D. Cancer supportive care, improving the quality of life for cancer patients. A program evaluation report. Support Care Cancer. 2004;12:293–301.
Article
PubMed
Google Scholar
Quintin C, Martinelli F, Coeans C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumour sites. Cancer. 2014;120:302–11.
Article
Google Scholar
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.
Article
CAS
PubMed
Google Scholar
Chan VTC, Yeo W. Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer Targets Ther. 2011;3:151–60.
CAS
Google Scholar
Temel JS, Greer JA, et al. Early palliative care for patients with metastatic non-small cell lung cancer. New Engl J Med. 2010;363:733–42.
Article
CAS
PubMed
Google Scholar
Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2:1447.
Article
CAS
PubMed
Google Scholar
Eli K, Nishimoto R, Mediansky L, Mantell J, Hamovitch M. Social relations, social support and survival among patients with cancer. J Psychosom Res. 1992;36:531–41.
Article
Google Scholar
Kroenke CH, Kubznsky LD, Schernhammer ES, Holmes LD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol. 2008;24:1010–111.
Google Scholar
Frenkel M, Gross S, Popper Giveon A, Sapire K, Hermoni D. Living outliers: experiences, insights and narratives of exceptional survivors of incurable cancer. Future Oncol. 2015;11:1741–9.
Article
CAS
PubMed
Google Scholar
Luciani F, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702–13.
Article
CAS
PubMed
Google Scholar
Zhang Y, et al. Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget. 2014;5(24):12936–49.
PubMed
PubMed Central
Google Scholar
Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–49.
Article
CAS
PubMed
Google Scholar
Xing Y, et al. Metabolic reprogramming of the tumour microenvironment. FEBS J. 2015;282(20):3892–8.
Article
CAS
PubMed
Google Scholar
Wang BY, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34:85.
Article
PubMed
PubMed Central
Google Scholar
Psutka SP, et al. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol Oncol. 2015;33(2):67.
Article
PubMed
Google Scholar
Smolkova K, et al. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol. 2011;43(7):950–68.
Article
CAS
PubMed
Google Scholar
Macintyre AN, Rathmell JC. Activated lymphocytes as a metabolic model for carcinogenesis. Cancer Metab. 2013;1(1):5.
Article
PubMed
PubMed Central
Google Scholar
Marelli-Berg FM, Fu H, Mauro C. Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity. Immunology. 2012;136(4):363–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17(7):2092–9.
Article
CAS
PubMed
Google Scholar
Zhu H, Zhou Z, Wang Y, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer. 2011;117(23):5423–31.
Article
PubMed
Google Scholar
Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42.
Article
PubMed
Google Scholar
Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative Group. N Engl J Med. 1999;341:476–84.
Article
CAS
PubMed
Google Scholar
Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2001;1:5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.
Article
CAS
PubMed
Google Scholar
Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71.
Article
PubMed
Google Scholar
Ready NE, PangHH GuL, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (alliance). J Clin Oncol. 2015;33(15):1660–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42–51.
Article
CAS
PubMed
Google Scholar
Byers LA, Krug LM, Waqar SN, et al. Improved small cell lung cancer (SCLC) response rates with veliparib and temozolomide: results from a Phase II trial. J Thorac Oncol. 2017;12(Suppl. 1):S406–7.
Article
Google Scholar
Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–95.
Article
CAS
PubMed
Google Scholar
Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(2):348–54.
Article
PubMed
Google Scholar
PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet (London, England). 1998;352:257–63.
Article
Google Scholar
Patel SH, Ma Y, Wernicke AG, Nori D, Chao KS, Parashar B. Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer. Lung Cancer (Amsterdam, Netherlands). 2014;84:156–60.
Article
Google Scholar
Perry MC, Kohman LJ, Bonner JA, Gu L, Wang X, Vokes EE, et al. A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: cancer and leukemia group B 9734. Clin Lung Cancer. 2007;8:268–72.
Article
CAS
PubMed
Google Scholar
Wu Y, Zhong W, Wang Q, Xu S, Mao W, Wu L, et al. Gefitinib (G) versus vinorelbine + cisplatin (VP) as adjuvant treatment in stage II–IIIA (N1–N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): a randomized, phase III trial (CTONG 1104). J Clin Oncol. 2017;35:8500.
Google Scholar
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Efficacy and safety of erlotinib vs vinorelbine/cisplatin as adjuvant therapy for stage IIIA EGFR mutant NSCLC patients. In: IASLC 18th world conference on lung cancer. 2017. p. 134.
Patel SC, Carpenter WR, Tyree S, Couch ME, Weissler M, Hackman T, et al. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol. 2011;29(11):1488–94.
Article
PubMed
Google Scholar